Does Aetna Cover Weight Loss Treatment in New Mexico? A 2026 Guide

Last updated: July 12, 2026

If you have Aetna health insurance in New Mexico and are researching weight loss treatment coverage, you have come to the right place. Aetna uses CVS/Caremark as its pharmacy benefit manager (PBM) for most commercial and ACA marketplace plans, and CVS/Caremark made a significant formulary change in 2026 that directly affects access to the most prescribed GLP-1 weight loss medications. This guide breaks down what Aetna and CVS/Caremark typically cover, what prior authorization (PA) criteria apply, and how to navigate the system as a New Mexico patient.

Ready to explore weight loss treatment options? Klarity Health connects you with licensed providers who can evaluate your eligibility and, if appropriate, prescribe FDA-approved weight loss medications. See if you may qualify →

The Biggest 2026 CVS/Caremark Update: Zepbound Is Back

The most important formulary development for Aetna/CVS Caremark weight loss patients in 2026 is the reinstatement of Zepbound (tirzepatide) on commercial CVS/Caremark formularies, effective October 1, 2026. CVS/Caremark had previously removed Zepbound from many of its commercial drug lists, creating a period where Aetna members often had only Wegovy as a covered GLP-1 option. As of October 1, 2026, Zepbound is typically Tier 3–4 with prior authorization required on CVS/Caremark commercial plans.

This is a meaningful differentiator compared to some other PBMs. Patients who were denied Zepbound under their Aetna plan earlier in the year may wish to resubmit a request after October 1, 2026 if their plan renews or updates its formulary in line with the CVS/Caremark commercial list.

Important note on the Medicare GLP-1 Bridge: As of July 1, 2026, CMS launched a Medicare GLP-1 Bridge program that provides Wegovy, Zepbound, and Foundayo at $50/month for eligible Medicare Advantage (MA) Part D members. This benefit is exclusively for Medicare Advantage enrollees — it does not apply to Aetna commercial, ACA marketplace, or employer-sponsored plans. If you have Aetna commercial insurance, this program does not affect your coverage.

CVS/Caremark Weight Loss Formulary for Aetna Members (2026)

The following reflects typical CVS/Caremark commercial formulary placement. Your specific Aetna plan document governs, and tier placement can vary by plan design. Always verify with your plan before starting treatment.

GLP-1 Receptor Agonists (FDA-Approved for Weight Loss)

Ozempic and Mounjaro note: Ozempic (semaglutide 1 mg/2 mg) and Mounjaro (tirzepatide) carry FDA indications for type 2 diabetes — not for obesity or weight management. CVS/Caremark commercial formularies and Aetna coverage policies generally do not cover Ozempic or Mounjaro for weight loss purposes on commercial plans. Patients who have heard that Ozempic and Wegovy are “the same drug” are correct about the active ingredient (semaglutide) but the coverage criteria key off FDA indication and dose. Requesting Ozempic for weight loss typically results in a coverage denial. Wegovy (2.4 mg) is the obesity-indicated dose.

Non-GLP-1 Weight Loss Medications

Prior Authorization Criteria for GLP-1s

CVS/Caremark typically requires the following documentation for GLP-1 weight loss medication PA on Aetna commercial plans:

• Confirmed BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documentation of participation in or referral to a lifestyle modification program (diet and exercise counseling)
• Absence of contraindications (personal or family history of medullary thyroid carcinoma or MEN2 for GLP-1 agonists)
• Prescribing provider attestation that the medication is medically necessary

PA timelines on Aetna/CVS Caremark plans typically follow federal standards: 72 hours for standard (non-urgent) requests and 24 hours for urgent clinical situations. Pharmacy PA requests are processed through CVS/Caremark (1-800-552-8159). Medical visit authorizations — if required for weight loss program visits — go through Aetna member services (1-800-872-3862). These are two separate processes run by two separate departments.

Electronic Prescribing for Controlled Substances (EPCS)

EPCS under New Mexico’s requirements (consistent with § 456.44 scope) applies exclusively to Schedule II controlled substances. None of the weight loss medications covered in this guide are Schedule II:

• GLP-1 medications (Wegovy, Zepbound, Saxenda) are not controlled substances
• Contrave and orlistat are not controlled substances
• Phentermine and Qsymia are Schedule IV controlled substances — not Schedule II — and therefore fall outside the EPCS mandate

EPCS is entirely inapplicable to weight loss treatment at Klarity Health. Providers may prescribe all covered weight loss medications using standard (non-EPCS) electronic or written prescribing workflows where state law permits.

New Mexico Coverage Frameworks for Weight Loss Treatment

Weight loss treatment coverage disputes in New Mexico are primarily governed by the ACA’s Essential Health Benefits (EHB) framework and individual plan documents — not by the New Mexico Mental Health Parity Act (NMSA 1978 § 59A-23E-19 et seq.), which applies specifically to mental health and substance use disorder benefits. Obesity treatment is not classified as a mental health condition under federal parity law.

Practically, this means:

• Aetna commercial plans are not required by state parity law to cover weight loss medications at the same level as other medical benefits
• ACA benchmark plan EHB standards determine minimum coverage obligations for individual and small-group marketplace plans
• Self-funded employer plans (subject to ERISA) are governed entirely by their plan documents — New Mexico state law generally does not apply to these plans
• Coverage for weight loss medications varies significantly between plan types and individual plan designs

If you receive a coverage denial for a weight loss medication that your provider has prescribed as medically necessary, you have the right to an internal appeal through Aetna and, if that is unsuccessful, an external independent review. The New Mexico Office of Superintendent of Insurance (NM OSI) can assist with appeals guidance at 1-855-427-5674.

Telehealth Weight Loss Treatment in New Mexico

New Mexico’s telehealth parity law requires that fully insured Aetna commercial plans cover telehealth services under the same terms as in-person care. This means weight loss consultations, follow-up visits for GLP-1 prescription management, and ongoing medication monitoring may be coverable through telehealth at the same cost-sharing as office visits, depending on your plan.

Klarity Health has 2,000+ licensed providers, including those who serve New Mexico patients via telehealth. After a clinical evaluation, Klarity providers can prescribe FDA-approved weight loss medications where clinically appropriate. Telehealth prescribing for non-controlled weight loss medications (Wegovy, Zepbound, Contrave, orlistat) proceeds under standard prescribing rules without additional federal restrictions.

Explore weight loss treatment with Klarity Health. Connect with a licensed provider to discuss your options — including GLP-1 medications if clinically appropriate for your situation. Check if you may qualify →

Navigating the Aetna + CVS/Caremark System

One of the most common patient frustrations with Aetna weight loss coverage is the two-department structure: pharmacy benefits are administered by CVS/Caremark, while medical visit benefits and clinical appeals go through Aetna directly. Patients are frequently redirected between departments when trying to resolve coverage issues. To avoid this:

• Pharmacy PA (for prescriptions): Contact CVS/Caremark at 1-800-552-8159. This is the number to call for formulary questions, PA submissions for medications, and pharmacy claim issues.
• Medical visit PA and clinical appeals: Contact Aetna member services at 1-800-872-3862. This covers visit authorizations, clinical necessity reviews, and formal appeals.
• NM OSI (insurance regulator): 1-855-427-5674 — for assistance with external reviews or filing a complaint about a coverage denial.

If you are on a 90-day maintenance supply of an oral weight loss medication, CVS/Caremark’s mail service pharmacy (Caremark Mail Service) may offer cost savings compared to retail 30-day fills.

Frequently Asked Questions

Does Aetna cover Wegovy in New Mexico?

Wegovy may be covered on Aetna commercial plans in New Mexico through CVS/Caremark formularies, typically at Tier 3–4 with prior authorization required. PA criteria generally include a BMI of ≥30 or ≥27 with a qualifying comorbidity, plus documentation of lifestyle modification efforts. Coverage and cost-sharing vary by plan — verify your specific benefits before starting treatment.

Does Aetna cover Zepbound in New Mexico?

As of October 1, 2026, Zepbound (tirzepatide) has been reinstated on CVS/Caremark commercial formularies. Aetna members whose plans follow the standard CVS/Caremark commercial list may now have Zepbound covered at Tier 3–4 with PA. If you were denied Zepbound coverage earlier in 2026 under your Aetna plan, it is worth requesting a new PA after your plan’s formulary update takes effect. Contact CVS/Caremark at 1-800-552-8159 to confirm whether your specific plan includes the reinstated Zepbound coverage.

Does the Medicare GLP-1 Bridge apply to my Aetna commercial plan?

No. The Medicare GLP-1 Bridge (launched July 1, 2026, providing Wegovy, Zepbound, and Foundayo at $50/month via CMS) is exclusively for Medicare Advantage (MA) Part D plan members. It does not apply to Aetna commercial, ACA marketplace, or employer-sponsored plans. If you have Aetna commercial insurance, your weight loss medication coverage is determined entirely by your CVS/Caremark pharmacy benefit.

Do I need a special prescription for Wegovy or Zepbound?

No special prescribing technology is required for GLP-1 weight loss medications. EPCS applies only to Schedule II controlled substances under federal and New Mexico law. Wegovy, Zepbound, and other GLP-1 medications are not controlled substances — they can be prescribed through standard electronic prescribing. Phentermine and Qsymia are Schedule IV, which also falls outside the EPCS mandate.

What can I do if my PA for a weight loss medication is denied?

If your PA is denied, you have the right to a first-level internal appeal through Aetna (1-800-872-3862). If the internal appeal is unsuccessful, you may request an external independent review through the New Mexico OSI (1-855-427-5674). Your provider can support the appeal by supplying additional clinical documentation, including BMI measurements, comorbidity records, and evidence of prior lifestyle modification attempts.

Can I get weight loss treatment through telehealth in New Mexico?

Yes. New Mexico’s telehealth parity provisions require fully insured Aetna commercial plans to cover telehealth services on the same terms as in-person care. Weight loss consultations and prescription management visits may qualify for telehealth coverage. Klarity Health’s licensed providers can evaluate your eligibility for FDA-approved weight loss medications via a telehealth visit. See if you may qualify →

Disclaimer: This page provides general information about how Aetna and CVS/Caremark typically handle weight loss treatment coverage in New Mexico. Coverage terms, formulary tiers, and PA criteria vary by individual plan and are subject to change. This is not a guarantee of coverage. Always verify your specific benefits with Aetna (1-800-872-3862) or CVS/Caremark (1-800-552-8159) before beginning treatment. The New Mexico Office of Superintendent of Insurance (1-855-427-5674) can assist with coverage disputes.